Omass Therapeutics offers a proprietary platform that combines custom biochemistry, native mass spectrometry, and specialized chemistry to study membrane proteins and intracellular complexes in a near‑physiological, cell‑free environment. The technology quantifies binding affinities, kinetics, and functional outcomes, enabling pharmaceutical and biotech R&D teams to identify and optimize small‑molecule leads, including low‑affinity and allosteric binders, for orphan and immune‑mediated diseases.
Funding
$12.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BPFounders
Product
Problem
Traditional drug discovery methods struggle to accurately assess targets that function within complex membrane environments or intracellular protein complexes, leading to false leads and missed opportunities for diseases with high unmet need, such as orphan and immunological disorders.
Solution
OMass Therapeutics applies a proprietary platform that preserves the native ecosystem of membrane proteins and intracellular complexes while delivering cell‑free precision. By combining custom biochemistry, native mass spectrometry, and specialized chemistry, the platform measures physical interactions, binding affinities, and functional outcomes directly in a near‑physiological context. This approach links binding events to biological function, enabling rational lead optimization and the identification of low‑affinity or allosteric binders that are invisible to conventional assays. The technology supports systematic screening of solute carriers, GPCRs, and inflammasome complexes, accelerating the discovery of small‑molecule therapeutics for orphan and immune‑mediated diseases.
Target Audience
Primary customers are pharmaceutical R&D organizations and biotech companies developing small‑molecule therapeutics against membrane proteins, solute carriers, GPCRs, or inflammasome complexes, particularly for orphan and immunological indications.
Features
- Proprietary biochemistry that retains downstream partners, lipid environments, and endogenous regulators during assays
- Patent‑protected native mass spectrometry providing high‑resolution measurement of protein‑ligand and protein‑protein interactions
- Custom chemistry compatible with mass spectrometry to interrogate binding kinetics, affinity ranges, and multiple functional readouts
- Ability to capture both high‑ and low‑affinity interactions, revealing starting points for challenging targets
- Detection of natural allosteric sites and endogenous modulators for exploitation in drug design
- Integrated workflow that combines the biological relevance of cell‑based assays with the quantitative precision of cell‑free methods